Iron-chelating therapy with the new oral agent ICL670 (Exjade®)

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Iron-chelation therapy is essential in iron-overloaded patients. The long-term efficacy of this approach has been demonstrated unequivocally with deferoxamine, which effectively controls iron concentrations, thereby limiting organ damage and preventing premature death. However, as deferoxamine is administered parenterally, poor compliance is a significant limitation to successful patient management. ICL670 (Exjade®) is a highly efficient and selective oral iron chelator. The results of phase I and phase II clinical studies indicate that ICL670 is at least as effective as current standard therapy (deferoxamine), with a tolerability and safety profile suitable for chronic, once-daily administration. These encouraging results have provided the rationale for the ongoing phase III programme, and offer physicians and patients the promise of an oral, once-daily, iron-chelating agent for the prevention and management of iron overload.

Original languageEnglish
Pages (from-to)289-298
Number of pages10
JournalBest Practice and Research: Clinical Haematology
Volume18
Issue number2 SPEC. ISS.
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Chelation
Deferoxamine
Iron
Iron Chelating Agents
Chelation Therapy
Premature Mortality
Iron Overload
Therapeutics
Chelating Agents
Physicians
Safety
deferasirox

Keywords

  • Chelation therapy
  • Haemosiderosis
  • Iron overload
  • Iron-chelating agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Iron-chelating therapy with the new oral agent ICL670 (Exjade®). / Cappellini, Maria D.

In: Best Practice and Research: Clinical Haematology, Vol. 18, No. 2 SPEC. ISS., 06.2005, p. 289-298.

Research output: Contribution to journalArticle

@article{6fd2c93961a54e0eb8a6f7dc64bfb689,
title = "Iron-chelating therapy with the new oral agent ICL670 (Exjade{\circledR})",
abstract = "Iron-chelation therapy is essential in iron-overloaded patients. The long-term efficacy of this approach has been demonstrated unequivocally with deferoxamine, which effectively controls iron concentrations, thereby limiting organ damage and preventing premature death. However, as deferoxamine is administered parenterally, poor compliance is a significant limitation to successful patient management. ICL670 (Exjade{\circledR}) is a highly efficient and selective oral iron chelator. The results of phase I and phase II clinical studies indicate that ICL670 is at least as effective as current standard therapy (deferoxamine), with a tolerability and safety profile suitable for chronic, once-daily administration. These encouraging results have provided the rationale for the ongoing phase III programme, and offer physicians and patients the promise of an oral, once-daily, iron-chelating agent for the prevention and management of iron overload.",
keywords = "Chelation therapy, Haemosiderosis, Iron overload, Iron-chelating agents",
author = "Cappellini, {Maria D.}",
year = "2005",
month = "6",
doi = "10.1016/j.beha.2004.09.002",
language = "English",
volume = "18",
pages = "289--298",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - Iron-chelating therapy with the new oral agent ICL670 (Exjade®)

AU - Cappellini, Maria D.

PY - 2005/6

Y1 - 2005/6

N2 - Iron-chelation therapy is essential in iron-overloaded patients. The long-term efficacy of this approach has been demonstrated unequivocally with deferoxamine, which effectively controls iron concentrations, thereby limiting organ damage and preventing premature death. However, as deferoxamine is administered parenterally, poor compliance is a significant limitation to successful patient management. ICL670 (Exjade®) is a highly efficient and selective oral iron chelator. The results of phase I and phase II clinical studies indicate that ICL670 is at least as effective as current standard therapy (deferoxamine), with a tolerability and safety profile suitable for chronic, once-daily administration. These encouraging results have provided the rationale for the ongoing phase III programme, and offer physicians and patients the promise of an oral, once-daily, iron-chelating agent for the prevention and management of iron overload.

AB - Iron-chelation therapy is essential in iron-overloaded patients. The long-term efficacy of this approach has been demonstrated unequivocally with deferoxamine, which effectively controls iron concentrations, thereby limiting organ damage and preventing premature death. However, as deferoxamine is administered parenterally, poor compliance is a significant limitation to successful patient management. ICL670 (Exjade®) is a highly efficient and selective oral iron chelator. The results of phase I and phase II clinical studies indicate that ICL670 is at least as effective as current standard therapy (deferoxamine), with a tolerability and safety profile suitable for chronic, once-daily administration. These encouraging results have provided the rationale for the ongoing phase III programme, and offer physicians and patients the promise of an oral, once-daily, iron-chelating agent for the prevention and management of iron overload.

KW - Chelation therapy

KW - Haemosiderosis

KW - Iron overload

KW - Iron-chelating agents

UR - http://www.scopus.com/inward/record.url?scp=14544276809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544276809&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2004.09.002

DO - 10.1016/j.beha.2004.09.002

M3 - Article

C2 - 15737891

AN - SCOPUS:14544276809

VL - 18

SP - 289

EP - 298

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 2 SPEC. ISS.

ER -